Aims/hypothesis The aims of the study were to evaluate the association between type 2 diabetes and the risk of death from any cancer and specific cancers in East and South Asians.
Introduction
There is emerging evidence of a link between type 2 diabetes and an increased risk of developing cancer and death from cancer. A meta-analysis estimated that diabetes was associated with a 17% and 21% increased risk of developing any cancer and death from any cancer, respectively [1] . However, most studies of the association between diabetes and cancer risk have been conducted in Western populations [2] . Epidemiological studies have documented consistent increases in the prevalence of diabetes across Asia [3, 4] . Some evidence suggests that, at any given BMI, Asians are more susceptible to insulin resistance and have a higher prevalence of diabetes in comparison with whites [5] . The risk of diabetes-related complications and comorbidities may be different in Asians and whites. Some evidence also suggests that cancer risk associated with diabetes is higher in Asians than in non-Asians [1] ; however, the data are inconclusive. Given the increasing prevalence of diabetes and diabetes risk factors in Asian populations [3, 4] , it is important to understand the effect of diabetes on cancer in Asians.
Several prospective studies of diabetes and site-specific cancer risk have been conducted in individual cohorts in East Asians. However, the majority of the studies have examined risk for one or only a few cancer sites [6] [7] [8] [9] [10] , included a small number of patients with diabetes [11, 12] , or failed to control for important potential confounding variables such as BMI or obesity [6-8, 12, 13] . Asia is heterogeneous, with higher cancer mortality found in East Asian countries such as China, Japan and South Korea (125-164 per 100,000 in men and 65-82 per 100,000 in women) than in South Asian countries such as Bangladesh and India (70-90 per 100,000 in men and 60-72 per 100,000 in women) [14] . However, no prospective cohort studies have investigated the influence of diabetes on cancer in South Asians. Large prospective studies on the association between diabetes and cancer at specific organ sites in Asian populations are therefore needed.
We conducted a pooled analysis to evaluate the association between baseline diabetes and risk of death from all cancers and site-specific cancers, in 19 Asian prospective cohorts in the Asia Cohort Consortium (ACC).
Methods
ACC Details of the ACC, an international collaboration committed to the study of the aetiology of diseases in Asian populations, have been presented elsewhere [15, 16] . Cohorts were identified through a systematic search of the literature in early 2008, followed by a survey that was sent to each cohort to assess data availability [16] . The ACC includes more than 20 cohorts representing Japan, China, South Korea, India, Taiwan, Bangladesh and Singapore. Cohort studies that were included in the present study are listed in Table 1 . Several of these cohorts have examined the association between diabetes and cancer risk [9, 17, 18] . Our study was approved by the institutional review board of the Fred Hutchinson Cancer Research Center (Seattle, WA, USA) and by the ethics committees of each individual cohort study.
Data manipulation Relevant data from each of the participating cohorts were transferred and harmonised at the ACC coordinating centre at the Fred Hutchinson Cancer Research Center. Harmonisation involved several rounds of discussions to ensure that variables were correctly interpreted and extracted. Data were checked for illogical or missing values, and queries were sent back for clarification. The distributions of individual variables were explored to identify false or Diabetes and outcome data The 19 participating cohorts included a total of 847,009 individuals. Self-reported data on diabetes at baseline were collected from all cohorts. Available data on other indicators of diabetes in some of the cohorts support the overall validity of these self-reported data. For instance, in the Bangladeshi cohort, glycosuria was measured in 11,122 (95%) members, and 62% of participants who tested positive for glycosuria also self-reported as having been diagnosed with diabetes by a physician, while 99.1% of those who tested negative reported no such history [19] . The result is comparable with that from high-income countries such as Japan, where the sensitivity and specificity of the questionnaire for diabetic hyperglycaemia were 46% and 98%, respectively [15, 20] . All the participating cohorts were required to have available baseline data on diabetes status (self-reported), BMI (measured or self-reported), cigarette-smoking status, age, sex, follow-up time, vital status and cause of death (ICD-9 [www.icd9data.com/2007/Volume1] or ICD-10 [www.who. int/classifications/icd/en/]). In the present analysis, we excluded participants with data missing on age (n = 528), baseline diabetes (n = 73,178) and vital status (n = 2775), and those for whom data on follow-up duration were invalid or missing (n = 2947). After these exclusions, 771,297 participants remained (391,619 men and 379,678 women). Information on the types of diabetes (i.e. type 1 or type 2) was not available; however, given that type 1 diabetes accounts for less than 3% of total diabetes in Asia [21] and that we included adult cohorts only, we assume the large majority would have had type 2 diabetes. Additional data were available from selected cohorts on alcohol drinking (17 cohorts), education (14 cohorts), urban/rural residence (18 cohorts), duration of diabetes (six cohorts), and diabetes treatment (four cohorts).
Cancer death was ascertained from the underlying causes of death recorded on death certificates or death records in East Asian cohorts and in the Mumbai cohort. A validated verbal autopsy questionnaire was used in the Bangladesh cohort [22] . Outcomes of interest included: death from any cancer and cancers of the oesophagus, stomach, colorectum, colon, rectum, liver, bile duct, pancreas, lung, breast, endometrium, cervix, ovary, prostate, bladder, kidney and thyroid, as well as lymphoma and leukaemia (electronic supplementary material [ESM] Table 1 ). Cancers of interest were selected based on prior literature on the association between diabetes and the risk of death from cancer [2, 23] .
Statistical analyses To examine the relationship between diabetes and the risk of death from cancer, we estimated HRs and 95% CIs based on Cox proportional hazards regression models that combined studies in a meta-analysis of individual participant data [24, 25] . The assumption of proportional hazards was examined by testing the cross-product terms between covariate variables and log function of survival time within individual cohorts; p values for all the terms were >0.10. In all analyses, the effect of diabetes on the risk of death from cancer was taken to be cohort-specific, assuming that the log-HR associated with diabetes had a fixed-effect component in each cohort that was common to all cohorts and a cohort-specific random effect that was normally distributed with mean zero.
Potential confounders included baseline age, sex, cigarette smoking (never/ever), BMI, alcohol consumption (never/ever), educational attainment (no formal education, primary, secondary, trade/technical, university degree, postgraduate degree, other) and urban residence. Likelihood-based methods were used to test for heterogeneity across studies or geographic regions by comparing models with and without interactions between cohort or geographic region and baseline diabetes status. Stratified analyses were conducted by sex. To evaluate the potential effect of reverse causation, analyses excluded person-years and deaths with fewer than 3 years of follow-up.
For any cancer and cancers with sufficient number of deaths among those with diabetes (n > 70) that were also associated with diabetes status in the main analyses, including colorectal cancer, liver cancer, gallbladder cancer, pancreatic cancer and breast cancer, we further performed stratified analyses among East Asians (China, Taiwan, Singapore, South Korea and Japan) and South Asians (Bangladesh and India); by baseline age (<60 or ≥60 years, the median among cancer deaths in the combined East and South Asians); by baseline smoking status (never/ever); by baseline alcohol consumption status (never/ever); and by baseline BMI (22.8 kg/m 2 , the median among cancer deaths), to evaluate whether the influence of diabetes was similar in different subgroups. In cohorts with the available information, sensitivity analyses were also conducted to: (1) further control for baseline status of hypertension or cardiovascular disease (CVD); (2) further control for baseline status of cancer; (3) exclude studies that were initially clinical trials; and (4) exclude prevalent cases of CVD and cancer at baseline. In a subgroup of six cohorts (n = 243,214) with data on age at first diagnosis of diabetes, diabetes duration at baseline was calculated as the difference between age at first diagnosis and age at enrolment. We conducted analyses to estimate HRs, comparing those with different diabetes duration (<5 or ≥5 years) with those without diabetes at baseline. A separate model was also conducted including only the diabetes cases to compare the risk of death from cancer by diabetes duration (<5 vs ≥5 years) and to estimate the p values of the comparisons. Similar analyses were conducted in a subgroup of four cohorts (n = 198,440) with data on current treatment of diabetes (yes/no). All statistical analyses were conducted using SAS, version 9.4 (SAS Institute, Cary, NC, USA) or Stata, version 14.0 (StataCorp LP, College Station, TX, USA). All tests were two-sided and p < 0.05 was considered statistically significant.
Results
After exclusions, the study comprised a total of 771,297 participants from 19 cohorts (Table 1) , including 658,611 East Asians and 112,686 South Asians. The participants were, on average, 53.9 years old at baseline and had a mean follow-up of 12.7 years. Across all studies, 50.8% were men and 65.3% of men were ever smokers. The diabetes prevalence was lowest in the Linxian General Population Trial Cohort Study in China (0.1%) and highest in the Singapore Chinese Health Study (9.0%). Overall, diabetes was statistically significantly associated with a higher risk of death from any cancer and from cancers of the colorectum, colon and rectum separately, liver, bile duct, gallbladder, pancreas, breast, endometrium, ovary, prostate, kidney and thyroid, as well as lymphoma ( Table 2 ). The association was strongest for cancers of the liver, endometrium and thyroid. After excluding the first 3 years of follow-up, the associations between diabetes and the risk of death from any cancer and site-specific cancers were not materially changed.
The pattern of the associations between diabetes and cancer mortality in men was similar to that seen overall (Fig. 1) . The risk of death from lymphoma, oesophageal cancer and stomach cancer associated with diabetes was greater in women than in men. There was evidence of effect modification by sex for lymphoma (p interaction < 0.01) and stomach cancer (p interaction = 0.02). The positive association between diabetes and any cancer was similar in East and South Asians, although the estimate in South Asians did not reach statistical significance, possibly owing to the small number of deaths in participants with diabetes (Fig. 2) . Excluding participants with a history of cancer, hypertension or CVD, and additional adjustment for these conditions did not change the strength of the (Fig. 2) . Similarly, a stronger association between diabetes and the risk of death from liver cancer and gallbladder cancer was observed in individuals <60 years compared with those ≥60 years (p interaction < 0.01). For pancreatic cancer, the risk of death associated with diabetes was stronger in individuals <60 years and in those with a BMI <22.8 kg/m 2 compared with the HRs observed in the respective counterparts; the interaction of diabetes with age and BMI was statistically significant (p interaction = 0.02 and 0.03, respectively). The positive association between diabetes and death from breast cancer remained robust with additional control for the influence of baseline cancer, hypertension or CVD, and among never smokers and never drinkers. The association was stronger in those with a lower BMI compared with those with a higher BMI, although the interaction was not statistically significant.
We further explored the relationship of duration and treatment of diabetes with the risk of death from cancer in cohorts with available data. Analyses were done for cancers with ten or more deaths among diabetic participants. With the exception of breast cancer, among diabetic participants the associations between diabetes of ≥5 years' duration at baseline and the risk of death from any cancer and colorectal cancer, liver cancer or pancreatic cancer were weaker than those related to diabetes of <5 years' duration; however, none of the differences in estimates was statistically significant (ESM Table 2 ). In cohorts with data on current treatment, participants currently treated for diabetes, compared with those not currently treated, tended to have a greater risk of death from any cancer and cancers of the liver, gallbladder and pancreas; however, the risk difference reached statistical significance for death from any cancer only (p = 0.03; ESM Table 3 ). Results from sensitivity analyses excluding studies that were initially clinical trials (Linxian General Population Trial Cohort Study) were essentially the same (data not shown).
Discussion
In this pooled analysis of 19 Asian cohorts including more than 771,000 participants followed for up to 21 years, diabetes was associated with a 26% increase in the risk of death from any cancer. Specifically, diabetes was related to an increased risk of death from colorectal cancer, liver cancer, bile duct cancer, gallbladder cancer, pancreatic cancer, breast cancer, endometrial cancer, ovarian cancer, prostate cancer, kidney cancer, thyroid cancer and lymphoma. The positive associations for any cancer, colorectal cancer, liver cancer, gallbladder cancer, pancreatic cancer and breast cancer remained across different strata of BMI, smoking status and alcohol Fig. 2 Subgroup analyses for the association between diabetes at baseline and mortality from any cancer, colorectal cancer, liver cancer, gallbladder cancer, pancreatic cancer and breast cancer. HRs were adjusted for sex, baseline age, BMI, cigarette smoking, alcohol consumption, educational attainment and urban residence. Results for breast cancer among ever smokers and ever drinkers are not presented because there were fewer than ten deaths among participants with diabetes at baseline.
a Analyses excluded people with missing information on history of cancer and data from the Seoul Male Cohort Study and Mumbai Cohort Study, which did not have data on previous diagnoses of cancer.
b Analyses excluded people with missing information on history of CVD or hypertension and data from the Mumbai Cohort Study drinking status. Consistently stronger associations were seen in individuals <60 years at enrolment than in their older counterparts for liver cancer, gallbladder cancer and pancreatic cancer.
Several studies have addressed the association of diabetes with the risk of death from any cancer. A pooled analysis of 97 prospective cohorts in 820,900 whites from the Emerging Risk Factors Collaboration (ERFC) reported an HR of 1.25 (95% CI 1.19, 1.31) for death from any cancer in people with diabetes compared with those without diabetes [26] . In a prospective cohort of one million US adults in Cancer Prevention Study II (CPS II), diabetes was associated with increases in the risk of death from any cancer of 7% and 11% in men and women, respectively [27] . A meta-analysis reported a summary relative risk of death from any cancer associated with diabetes of 1.32 (95% CI 1.20, 1.45) based on three studies in Asians, and 1.16 (95% CI 1.01, 1.34) based on 14 studies in non-Asians [1] . In the present pooled analysis of Asians, we report an HR of 1.26 (95% CI 1.21, 1.31) for death from any cancer associated with diabetes. In CPS II, diabetes was positively related to death from cancers of the colon, liver or intrahepatic bile duct, pancreas, breast, endometrium, prostate (reduced risk) and bladder (in men only) [27] . The ERFC study reported that diabetes was moderately associated with death from cancers of the colorectum, liver, pancreas, breast, ovary, lung and bladder [26] . Our observed cancer-specific associations are largely consistent with these reports from two large studies in cohorts from Western countries on digestive cancers (including cancers of the colorectum, liver, bile duct, gallbladder and pancreas), as well as breast cancer. These data together suggest that the influence of diabetes on the risk of death from overall cancer, digestive cancers and breast cancer is largely similar in Asians and in developed Western countries.
The moderate associations between diabetes and the risk of death from liver and pancreatic cancer observed in our analyses are consistent with previous studies [2, 28] . A recent metaanalysis of 25 prospective studies of Asians and whites reported a twofold higher risk of liver cancer associated with diabetes, after controlling for alcohol intake, cirrhosis and viral hepatitis B or C infection [29] . However, reverse causation has been suspected, as mechanistic studies found that pancreatic cancer causes paraneoplastic beta cell dysfunction by shedding exosomes containing adrenomedullin and CA19-9 into circulation that inhibit insulin secretion [30] . In our subgroup analyses, although we observed that diabetes of short duration was more strongly related to the risk of cancer compared with diabetes of long duration, the difference was not statistically significant and the risk associated with diabetes of long duration remained elevated. A recent meta-analysis of 36 cohort studies reported that summary relative risks of pancreatic cancer remained elevated when excluding diabetes of short duration [31] , suggesting that reverse causation does not account for all the association. The higher risk of liver cancer and pancreatic cancer in diabetes could potentially be related to exposure of these organs to particularly elevated insulin in people with diabetes, particularly if the tumour cells remain sensitive to insulin [23, 32] . In the present study, a stronger association seen in younger participants for liver, gallbladder and pancreatic cancer also supports metabolic dysfunction (more predominant in the early years of diabetes because of insulin resistance [33] ) as being involved in the association between diabetes and these cancers. Taken together, given the magnitude of the associations and the consistent data across studies and different populations, diabetes control should be considered in cancer prevention for these cancers in Asians, especially for liver cancer, which has a high incidence in Asians.
Available data on the association between diabetes and colorectal cancer mortality are limited but are generally consistent with our findings [26, 34] . In addition to hyperinsulinaemia, hypothesised mechanisms include the slower bowel transit time and the elevated faecal bile acid concentrations related to diabetes [32] . We also found that diabetes was related to a 30-40% increased risk of death from gallbladder cancer and bile duct cancer, consistent with previous meta-analyses in whites and Asians [35, 36] . Aside from hyperinsulinaemia and resultant high levels of insulin-like growth factors, possible explanations for the increased risk include the propensity of diabetic individuals to develop gallstones [37] , and increased production of biliary cholesterol and lithogenic bile salts as a result of insulin resistance, which also directly promotes the formation of gallstones [38] .
We observed positive associations of diabetes with the risk of death from breast cancer, endometrial cancer, ovarian cancer, prostate cancer, kidney cancer, thyroid cancer and lymphoma. Hormone-related mechanisms, such as increases in bioavailable oestrogen, stimulation of endometrial stromal cells, increases in androgen synthesis and increases in endogenous sex steroids [23] due to increased circulating insulin, may underlie the associations for breast and other female cancers. Cumulative epidemiological evidence suggests an association between diabetes and breast cancer [34] . Genetic factors have emerged that potentially contribute to the associations with some female cancers [39, 40] . Data on ovarian cancer are less well established, possibly due to small sample sizes in existing studies, including the present analysis. Further large studies are needed to confirm and investigate effect modifiers for the influence of diabetes on less common hormone-related female cancers such as ovarian cancer in Asians.
Consistent with other prospective studies of cancer mortality in both whites [27, 41] and Asians [42] , we did not observe an association between diabetes and the risk of lung cancer mortality. The association with mortality from oesophageal cancer and stomach cancer in whites and Asians has been generally null [26, 27, 42] , except for a South Korean study, which found a positive association between diabetes and the risk of death from both cancers in men [28] . By contrast, we observed an increased risk of death from these two cancers that was confined to women. The lack of consistency may be caused by the heterogeneous nature of these cancers (each has subtypes with different aetiologies). Future studies are needed to investigate associations by subtypes of cancer and to explore whether other sex-specific risk differences, such as in the pattern and extent of alcohol drinking, can explain the difference by sex. Evidence of the association between diabetes and kidney cancer, thyroid cancer and lymphoma has also been inconsistent, although meta-analyses have suggested positive associations between diabetes and these cancers [43] [44] [45] . Two cohort studies in Asians reported a statistically significant increase in the risk of thyroid cancer incidence or mortality among diabetic patients [10, 13] . We observed moderate associations for kidney (HR 1.84; 95% CI 1.28, 2.64) and thyroid (HR 1.99; 95% CI 1.03, 3.86) cancer in Asians, suggesting that the effects of diabetes on these cancers may be greater than those observed in whites. However, future larger studies that include information on subtypes of these cancers are needed to confirm the associations in Asians.
For prostate cancer, most of the studies that found an inverse association were conducted in whites [27, 46] . Studies in Asians generated inconsistent findings, and a meta-analysis of studies in Asians concluded that there was a positive association [47] . The influence of diabetes on prostate cancer in Asians and whites appears different, possibly due to differences in incidence rates, screening, diagnosis and treatment in the two populations. In addition, because the outcomes in this study are based on mortality data, they reflect the combined influence of diabetes on disease incidence and survival. Additional studies with incidence data in Asians are warranted, as such data are critical for prostate cancer, for which there is a greater difference between cancer incidence and cancer mortality, compared with other cancers such as liver and pancreatic cancers, which have a shorter survival time.
Major strengths of the present study included a large sample size of diverse Asian populations, allowing us to conduct several sensitivity analyses and stratified analyses by sex, age, smoking status and alcohol consumption. In addition, we had detailed data at the individual level from all cohorts for covariate adjustments and exploration of heterogeneity, avoiding some drawbacks of meta-analysis based on aggregate data from published results. In addition, we included a comprehensive list of causes of cancer death. A limitation of our study is the use of self-reported diabetes status and the lack of update on diabetes status during follow-up. This might have resulted in non-differential misclassification. In a subgroup analysis, we found that the association between treated diabetes and cancer was stronger than that between untreated diabetes and cancer, suggesting that the use of a more stringent definition of diabetes may reduce this misclassification. The use of selfreported information prevented us from distinguishing between type 1 and type 2 diabetes; however, type 2 diabetes accounts for more than 90% of diabetes [16, 48] . Certain diabetes treatments have been reported to increase (e.g. exogenous insulin) or decrease (e.g. metformin) the risk of cancer [23, 49, 50] , but our pooled analyses cannot address the influence of specific treatments, due to the lack of data. We had data on the absence and presence of current treatment only in a small subset of cohorts. Finally, we have limited sample sizes to evaluate the influence of diabetes on site-specific cancers in South Asians. Given that South Asian populations are undergoing an epidemiological transition, there is an emerging need for cohort studies to be conducted for cancer risk factors.
Conclusion We observed that diabetes was related to an increased risk of death from any cancer, colorectal cancer, liver cancer, bile duct cancer, gallbladder cancer, pancreatic cancer, breast cancer, endometrial cancer, ovarian cancer, prostate cancer, kidney cancer, thyroid cancer and lymphoma in Asians. The findings indicate a potential need for appropriate cancer screening among individuals with diabetes and a greater emphasis on lifestyle modifications related to cancer mortality not only in Western populations but also in Asians. We also found an increased risk associated with diabetes from other cancers, which requires future confirmation.
